The settlement removes a significant legal overhang and provides a recurring revenue stream tied to Ascendis's Yuviwel sales. Monitor for the final definitive agreement by September 24, 2026, and for Ascendis's commercial launch trajectory in achondroplasia to gauge the magnitude of BioMarin's future royalty income.
Price Chart
Executive Summary
BioMarin entered a binding term sheet with Ascendis Pharma to settle all global patent litigation. Ascendis will pay BioMarin a royalty of 20% of net sales of Yuviwel in the U.S. (retroactive to first commercial sale) and 18% in the EU, Brazil, and South Korea until May 2030. The deal removes legal overhang and establishes a long-term revenue stream tied to Ascendis's achondroplasia product, but no upfront payment or near-term revenue guidance was provided.
Key Financial Metrics
Key Facts
- BioMarin entered a binding term sheet with Ascendis Pharma resolving all global patent litigation, including an ITC Section 337 investigation.
- Ascendis will pay a royalty of 20% of annual net sales of Yuviwel in the U.S. and 18% in the EU, Brazil, and South Korea until May 2030.
- Royalties are retroactive to the date of first commercial sale in each territory.
- The license covers Yuviwel for all current and potential indications, including achondroplasia and hypochondroplasia, and combination therapies.
- BioMarin will dismiss with prejudice all pending litigation related to its patent rights.
- The term sheet includes a mutual regulatory non-interference clause, a covenant by Ascendis not to challenge BioMarin's patents, and a release of past infringement claims.
- Parties have until September 24, 2026 to finalize the definitive agreement; the term sheet remains binding if no agreement is reached by then.
Financial Impact
BioMarin receives a royalty stream equal to 20% of U.S. net sales and 18% of net sales in EU, Brazil, and South Korea of Yuviwel until May 2030, retroactive to first commercial sale. The filing does not disclose current or projected Yuviwel sales, so total value is not quantifiable from this document alone.
Risk Factors
- Yuviwel sales may be lower than expected, limiting the royalty revenue to BioMarin.
- Execution of the definitive agreement could be delayed or fail, though the term sheet remains binding.
- No upfront cash consideration was disclosed, so immediate financial impact is dependent on future sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-375275 |
| Document: d110137dex991.htm | 0001193125-26-375275 |
| Document: 0001193125-26-375275-index-headers.html | 0001193125-26-375275 |
| Document: 0001193125-26-375275-index.html | 0001193125-26-375275 |
| Document: 0001193125-26-375275.txt | 0001193125-26-375275 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $64.45 $63.94 | ▼ −0.79% | ▼ −1.61% | $57.18 (−11.28%) |
Sep 14, 2026 18d ago | 8-K | $66.41 $64.06 | ▼ −3.54% | ▼ −3.65% | $57.18 (−13.90%) |
Sep 1, 2026 4w ago | 8-K | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.18 (−11.81%) |
Sep 1, 2026 4w ago | Press Release | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.18 (−11.81%) |
Aug 31, 2026 4w ago | 8-K | $65.23 $64.63 | ▼ −0.92% | ▼ −0.78% | $57.18 (−12.34%) |
Aug 18, 2026 6w ago | 8-K | $66.99 $66.12 | ▼ −1.30% | ▼ −1.10% | $57.18 (−14.64%) |
Jun 4, 2026 17w ago | 8-K | $56.77 $55.95 | ▼ −1.44% | ▼ −2.01% | $57.18 (+0.72%) |
Apr 27, 2026 22w ago | 8-K | $53.62 $55.42 | ▲ +3.36% | ▲ +2.96% | $57.18 (+6.63%) |
Apr 21, 2026 23w ago | DEFA14A | $54.16 $53.24 | ▼ −1.71% | ▼ −1.76% | $57.18 (+5.57%) |
Feb 28, 2026 30w ago | Institutional Cluster | $59.71 $60.65 | ▲ +1.57% | ▲ +2.78% | $57.18 (−4.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access